about
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid InhibitorsInhibition of influenza A virus (H1N1) fusion by benzenesulfonamide derivatives targeting viral hemagglutininExploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins.Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.Design and synthesis of benzenesulfonamide derivatives as potent anti-influenza hemagglutinin inhibitorsDiscovery of novel 1-phenyl-cycloalkane carbamides as potent and selective influenza fusion inhibitors.Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins.Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular MechanismsDiscovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) InhibitorsSynthesis of 7-substituted benzolactam-V8s and their selectivity for protein kinase C isozymesIdentification of New ATG4B Inhibitors Based on a Novel High-Throughput Screening PlatformA New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles
P50
Q27722081-E5603570-754C-414B-B0BF-50206D52194FQ28478448-43799146-FD9A-42F8-B844-6A4E41996A1EQ30010956-9BDDF444-4096-4C28-A9B8-F11B5441313DQ35264946-90F45B14-81E9-45C8-ACA5-944439EEEB49Q36857420-F93B3F2E-0F2A-43A8-A39C-E72BDCDF75F1Q36876670-BB49BA62-9549-4CE9-9553-C1ECA8E86BE0Q38904307-1AA781F2-7376-4F6E-BD2E-3E3BD0FB1B27Q39260605-925A82E2-426B-4CEC-96C2-E8B1A43DA221Q39512741-FD47D536-2F58-4FC4-9CEF-7A6E13395311Q39701274-0B97602F-AC8F-4B44-A9EA-33B219EE83B3Q40018481-3A09E4F9-6CB6-4345-82EB-C656EC85FD6CQ40221493-41CBFE9C-49BC-406F-B6F5-8FF0037FF38EQ40275652-AC555490-2B62-4550-A8D9-D14171F875FDQ40330419-A2A282E1-986F-469F-9109-B7162315BDBAQ42358773-62F3FB2E-9AFB-4E87-9036-5FE80B4781C8Q74412882-4711BB52-EA97-4B6A-B03A-D2EEA9B66A9EQ87493028-BAFE71BF-C2D9-4D32-8EED-D45BAF9AF377Q91122142-3FEF6EE3-1A84-4C0A-8BFC-59C10F98DF7C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Guozhi Tang
@ast
Guozhi Tang
@en
Guozhi Tang
@es
Guozhi Tang
@sl
type
label
Guozhi Tang
@ast
Guozhi Tang
@en
Guozhi Tang
@es
Guozhi Tang
@sl
prefLabel
Guozhi Tang
@ast
Guozhi Tang
@en
Guozhi Tang
@es
Guozhi Tang
@sl
P106
P1153
36028883600
P31
P496
0000-0002-7131-4678